← Leaderboards
Roland Bruno Walter
Fred Hutchinson Cancer Center
$12,142,218
Attributed
$14,321,902
Total exposure
14
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.8M · FY2009–25$5M$3.8M$2.5M$1.3M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,396,815 · 15
By mechanism
R01$6,248,831 · 2
R21$3,972,925 · 9
R37$3,788,191 · 1
P01$2,265,632 · 2
K23$121,236 · 1
Top collaborators
- Hans-Peter Kiem5 shared
- Jatinder K. Lamba3 shared
- Megan Othus2 shared
- Brenda Marie Sandmaier1 shared
Most similar at Fred Hutchinson Cancer Center
Same institution · by research overlap
- Hans-Peter Kiem$98,160,227
- George S Laszlo$485,634
Others in their field
Top investigators on “Antibodies”
- Lawrence Corey · Fred Hutchinson Cancer Center$525,765,536
- Bambra Strokes · Ppd Development Lp$461,655,950
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$385,009,925
- Barton F Haynes · Duke University$372,611,596
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$323,573,074
- Dennis R. Burton · Scripps Research Institute$306,733,901
Research focus
AntibodiesVariantToxic EffectIn VivoCellsImproved OutcomeInterestCell SurfaceMouse ModelAcute Myelocytic LeukemiaLeukemiaGemtuzumab OzogamicinAntigensBasePreclinical StudyAntibody-Drug ConjugatesHumanized MouseCell KillingGlycoproteinsRadioimmunotherapyAstatineLeukemic Stem CellRadioisotopesHematopoietic
Grant awards (41)
Preventing Relapse After Non-myeloablative Stem Cell Transplantation: The Final Challenge$2,074,913
P01 · FY2025 · CA
Base-Edited Hematopoietic Stem and Progenitor Cells To Enable Safe Use Of Highly Potent CD33-Targeted Radioimmunotherapy$850,173
R01 · FY2025 · CA · contact PI
Novel Approaches to CD33-Directed Radioimmunotherapy$657,666
R37 · FY2025 · CA · contact PI
Core C: Administrative Services$190,719
P01 · FY2025 · CA · contact PI
Novel Approaches to CD33-Directed Radioimmunotherapy$825,157
R37 · FY2024 · CA · contact PI
Base-Edited Hematopoietic Stem and Progenitor Cells To Enable Safe Use Of Highly Potent CD33-Targeted Radioimmunotherapy$440,557
R01 · FY2024 · CA · contact PI
Development of 211Astatine-Conjugated Anti-CD45 Antibody-Based Conditioning for Hematopoietic Stem Cell Gene Therapy and Editing$861,939
R01 · FY2023 · HL · contact PI
Base-Edited Hematopoietic Stem and Progenitor Cells To Enable Safe Use Of Highly Potent CD33-Targeted Radioimmunotherapy$724,829
R01 · FY2023 · CA · contact PI
Novel Approaches to CD33-Directed Radioimmunotherapy$623,487
R37 · FY2023 · CA · contact PI
CD117-Targeted Radioimmunotherapy with Astatine-211 for Acute Myeloid Leukemia and Myelodysplastic Syndrome$236,878
R21 · FY2023 · CA · contact PI
Development of 211Astatine-Conjugated Anti-CD45 Antibody-Based Conditioning for Hematopoietic Stem Cell Gene Therapy and Editing$869,409
R01 · FY2022 · HL · contact PI
Base-Edited Hematopoietic Stem and Progenitor Cells To Enable Safe Use Of Highly Potent CD33-Targeted Radioimmunotherapy$742,957
R01 · FY2022 · CA · contact PI
Novel Approaches to CD33-Directed Radioimmunotherapy$610,755
R37 · FY2022 · CA · contact PI
CD117-Targeted Radioimmunotherapy with Astatine-211 for Acute Myeloid Leukemia and Myelodysplastic Syndrome$218,488
R21 · FY2022 · CA · contact PI
Optimizing NK Cell-Engaging Bispecific Antibody Therapy Targeting CD33$201,587
R21 · FY2022 · CA · contact PI
Novel Approaches to CD33-Directed Radioimmunotherapy$149,050
R37 · FY2022 · CA · contact PI
Development of 211Astatine-Conjugated Anti-CD45 Antibody-Based Conditioning for Hematopoietic Stem Cell Gene Therapy and Editing$877,086
R01 · FY2021 · HL · contact PI
Novel Approaches to CD33-Directed Radioimmunotherapy$235,803
R37 · FY2021 · CA · contact PI
Optimizing NK Cell-Engaging Bispecific Antibody Therapy Targeting CD33$163,219
R21 · FY2021 · CA · contact PI
CAR T-Cell Therapy Targeting the Membrane-Proximal C2-Set Domain of CD33 for Treatment of Acute Myeloid Leukemia and Other CD33-Expressing Hematopoietic Neoplasms$157,326
R21 · FY2021 · CA · contact PI
Optimization of Siglec-8-Directed Immunotherapy for Eosinophilic and Mast Cell Disorders$113,858
R21 · FY2021 · AI · contact PI
Optimization of Siglec-8-Directed Immunotherapy for Eosinophilic and Mast Cell Disorders$106,142
R21 · FY2021 · AI · contact PI
CAR T-Cell Therapy Targeting the Membrane-Proximal C2-Set Domain of CD33 for Treatment of Acute Myeloid Leukemia and Other CD33-Expressing Hematopoietic Neoplasms$89,514
R21 · FY2021 · CA · contact PI
Optimizing NK Cell-Engaging Bispecific Antibody Therapy Targeting CD33$83,621
R21 · FY2021 · CA · contact PI
Development of 211Astatine-Conjugated Anti-CD45 Antibody-Based Conditioning for Hematopoietic Stem Cell Gene Therapy and Editing$1
R01 · FY2021 · HL · contact PI
Development of 211Astatine-Conjugated Anti-CD45 Antibody-Based Conditioning for Hematopoietic Stem Cell Gene Therapy and Editing$881,880
R01 · FY2020 · HL · contact PI
Novel Approaches to CD33-Directed Radioimmunotherapy$686,273
R37 · FY2020 · CA · contact PI
Optimization of Siglec-8-Directed Immunotherapy for Eosinophilic and Mast Cell Disorders$264,000
R21 · FY2020 · AI · contact PI
CAR T-Cell Therapy Targeting the Membrane-Proximal C2-Set Domain of CD33 for Treatment of Acute Myeloid Leukemia and Other CD33-Expressing Hematopoietic Neoplasms$205,700
R21 · FY2020 · CA · contact PI
Novel Approach to CD33-Targeted Immunotherapy of Acute Myeloid Leukemia$184,296
R21 · FY2020 · CA · contact PI
Novel Approach to CD33-Targeted Immunotherapy of Acute Myeloid Leukemia$236,741
R21 · FY2019 · CA · contact PI
Treatment of Acute Myeloid Leukemia with C2-Set Domain-Specific CD33 Antibodies$222,789
R21 · FY2019 · CA · contact PI
Treatment of Acute Myeloid Leukemia with C2-Set Domain-Specific CD33 Antibodies$191,400
R21 · FY2018 · CA · contact PI
Prediction of Treatment-Related Mortality and Therapeutic Resistance in AML$195,938
R21 · FY2015 · CA · contact PI
Prediction of Treatment-Related Mortality and Therapeutic Resistance in AML$234,219
R21 · FY2014 · CA · contact PI
Prognostic and Functional Significance of Adhesion Molecules in Pediatric AML$150,559
R21 · FY2013 · CA · contact PI
Impact of genetic variation on response to GO therapy in COG-AML clinical trials$107,877
R21 · FY2013 · CA
Impact of genetic variation on response to GO therapy in COG-AML clinical trials$86,333
R21 · FY2013 · CA
Prognostic and Functional Significance of Adhesion Molecules in Pediatric AML$277,753
R21 · FY2012 · CA · contact PI
Impact of genetic variation on response to GO therapy in COG-AML clinical trials$244,687
R21 · FY2012 · CA
AML Stem Cell Heterogeneity: Implications for Gemtuzumab Ozogomicin-based Therapy$121,236
K23 · FY2009 · CA · contact PI